Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer

Sawada,Yu; Komori,Hiroyuki; Tsunoda,Yoshiyuki; Shimomura,Manami; Takahashi,Mari; Baba,Hideo; Ito,Masaaki; Saito,Norio; Kuwano,Hiroyuki; Endo,Itaru; Nishimura,Yasuharu; Nakatsura,Tetsuya

doi:10.3892/or.2013.2941

Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer

Authors:
- Yu Sawada
- Hiroyuki Komori
- Yoshiyuki Tsunoda
- Manami Shimomura
- Mari Takahashi
- Hideo Baba
- Masaaki Ito
- Norio Saito
- Hiroyuki Kuwano
- Itaru Endo
- Yasuharu Nishimura
- Tetsuya Nakatsura
View Affiliations

Affiliations: Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan, Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan, Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan, Colorectal and Pelvic Surgery Division, National Cancer Center Hospital East, Kashiwa 277-8577, Japan, Department of General Surgical Science (Surgery I), Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan, Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan
Published online on: December 20, 2013 https://doi.org/10.3892/or.2013.2941
Pages: 1051-1058
Copyright: © Sawada et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously reported that heat shock protein 105 (HSP105) is overexpressed in a variety of human cancers, including colorectal, pancreatic and esophageal cancer and has proven to be a novel biomarker for the immunohistochemical detection of these cancers. In the present study, we used HLA-transgenic mice (Tgm) and the peripheral blood mononuclear cells (PBMCs) of colorectal cancer patients to identify HLA-A2 and HLA-A24-restricted HSP105 epitopes, as a means of expanding the application of HSP105-based immunotherapy to HLA-A2- or HLA-A24-positive cancer patients. In addition, we investigated by ex vivo IFN-γ ELISPOT assay whether the HSP105-derived peptide of cytotoxic T cells (CTLs) exists in PBMCs of pre-surgical colorectal cancer patients. We found that four peptides, HSP105 A2-7 (RLMNDMTAV), HSP105 A2-12 (KLMSSNSTDL), HSP105 A24-1 (NYGIYKQDL) and HSP105 A24-7 (EYVYEFRDKL), are potential HLA-A2 or HLA-A24-restricted CTL HSP105-derived epitopes. HSP105-specific IFN-γ-secreting T cells were detected in 14 of 21 pre-surgical patients with colorectal cancer in response to stimulation with these four peptides. Our study raises the possibility that these HSP105 peptides are applicable to cancer immunotherapy in patients with HSP105-expressing cancer, particularly colorectal cancer.

View Figures

View References

1	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar
2	Mlecnik B, Tosolini M, Kirilovsky A, et al: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
3	Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M and Nishimura Y: Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun. 281:936–944. 2001. View Article : Google Scholar : PubMed/NCBI
4	Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y and Ogawa M: Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep. 10:1777–1782. 2003.PubMed/NCBI
5	Hatayama T, Yasuda K and Nishiyama E: Characterization of high-molecular-mass heat shock proteins and 42 degrees C-specific heat shock proteins of murine cells. Biochem Biophys Res Commun. 204:357–365. 1994. View Article : Google Scholar : PubMed/NCBI
6	Miyazaki M, Nakatsura T, Yokomine K, Senju S, Monji M, Hosaka S, et al: DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T-cells and CD8 T-cells. Cancer Sci. 96:695–705. 2005. View Article : Google Scholar : PubMed/NCBI
7	Yokomine K, Nakatsura T, Minohara M, et al: Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice. Biochem Biophys Res Commun. 343:269–278. 2006. View Article : Google Scholar : PubMed/NCBI
8	Yokomine K, Nakatsura T, Senju S, Nakagata N and Minohara M: Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc(Min/+) mice. Cancer Sci. 98:1930–1935. 2007.PubMed/NCBI
9	Browning M and Krausa P: Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today. 17:165–170. 1996. View Article : Google Scholar : PubMed/NCBI
10	Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA and Pérarnau B: HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 185:2043–2051. 1997.PubMed/NCBI
11	Firat H, Garcia-Pons F, Tourdot S, et al: H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol. 29:3112–3121. 1999. View Article : Google Scholar : PubMed/NCBI
12	Hosaka S, Nakatsura T, Tsukamoto H, Hatayama T, Baba H and Nishimura Y: Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci. 97:623–632. 2006. View Article : Google Scholar : PubMed/NCBI
13	Komori H, Nakatsura T, Senju S, et al: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 12:2689–2697. 2006. View Article : Google Scholar : PubMed/NCBI
14	Nakatsura T, Komori H, Kubo T, et al: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res. 10:8630–8640. 2004. View Article : Google Scholar : PubMed/NCBI
15	Nakatsura T, Senju S, Ito M, Nishimura Y and Itoh K: Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol. 32:826–836. 2002. View Article : Google Scholar
16	Yoshitake Y, Nakatsura T, Monji M, et al: Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 10:6437–6448. 2004. View Article : Google Scholar
17	Monji M, Nakatsura T, Senju S, et al: Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 10:6047–6057. 2004. View Article : Google Scholar : PubMed/NCBI
18	Feder ME and Hofmann GE: Heat-shock proteins, molecular chaperones and the stress response: evolutionary and ecological physiology. Annu Rev Physiol. 61:243–282. 1999. View Article : Google Scholar : PubMed/NCBI
19	Craig EA, Weissman JS and Horwich AL: Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell. 78:365–372. 1994. View Article : Google Scholar : PubMed/NCBI
20	Hwang TS, Han HS, Choi HK, et al: Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol. 18:690–700. 2003. View Article : Google Scholar : PubMed/NCBI
21	Kawakami Y and Rosenberg SA: Human tumor antigens recognized by T-cells. Immunol Res. 16:313–339. 1997. View Article : Google Scholar : PubMed/NCBI
22	van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991.
23	Kawakami Y, Eliyahu S, Delgado CH, et al: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 91:6458–6462. 1994. View Article : Google Scholar : PubMed/NCBI
24	Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 20:395–425. 2002. View Article : Google Scholar
25	Hickman-Miller HD and Hildebrand WH: The immune response under stress: the role of HSP-derived peptides. Trends Immunol. 25:427–433. 2004. View Article : Google Scholar : PubMed/NCBI
26	Romero P, Cerottini JC and Speiser DE: Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother. 53:249–255. 2004. View Article : Google Scholar : PubMed/NCBI
27	Jäger E, Chen YT, Drijfhout JW, et al: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 187:265–270. 1998.
28	Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH and Fernando GJ: Antigen-specific CD4⁺T-cell help is required to activate a memory CD8⁺T-cell to a fully functional tumor killer cell. Cancer Res. 62:6438–6441. 2002.PubMed/NCBI